“Twice daily dermal administration of tapinarof cream at doses of 0 (vehicle), 0.5, 1.0 and 3.0% (Formulation F; 0, 10, 20, and 60 mg/kg/day) were applied onto 10% of total BSA of minipigs (3/sex/group) with no occlusion for 39 weeks.”
✓ VerifiedFDA multi-discipline review, p. 40Source ↗
Pivotal GLP studies
26-week subcutaneous rat and 39-week dermal minipig studies
“Tapinarof (GSK2894512; WBI-1001) has been evaluated in single- and repeat-dose dermal toxicity studies of up to 13 weeks in mice and rats, 28 days in rabbits, and up to 39 weeks in minipigs. Tapinarof was also evaluated in repeat-dose subcutaneous toxicity studies of up to 26 weeks in rats.”
✓ VerifiedFDA multi-discipline review, p. 30Source ↗
Route in tox
Dermal (minipig) and subcutaneous (rat)
“Tapinarof (GSK2894512; WBI-1001) has been evaluated in single- and repeat-dose dermal toxicity studies of up to 13 weeks in mice and rats, 28 days in rabbits, and up to 39 weeks in minipigs. Tapinarof was also evaluated in repeat-dose subcutaneous toxicity studies of up to 26 weeks in rats.”
✓ VerifiedFDA multi-discipline review, p. 30Source ↗